Diagnosing and treating opioid dependence

Journal of Family Practice

Volumn 61, Issue 10, 2012, Pages

  Hill, Kevin P ^a,b   Rice, Lindsay S ^a   Connery, Hilary S ^a,b   Weiss, Roger D ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; CLONIDINE; DICYCLOVERINE; METHADONE; MU OPIATE RECEPTOR; NALTREXONE; OXYCODONE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CASE REPORT; DEPRESSION; DROWSINESS; DRUG COST; DRUG DEPENDENCE TREATMENT; DRUG HALF LIFE; DRUG MISUSE; DRUG RECEPTOR BINDING; FAMILY THERAPY; FOLLOW UP; HUMAN; INSOMNIA; MAINTENANCE CHEMOTHERAPY; MALE; NAUSEA; NOMENCLATURE; OPIATE ADDICTION; PATIENT ASSESSMENT; PRESCRIPTION; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; SCREENING TEST; SIDE EFFECT; UNEMPLOYMENT; WEIGHT GAIN; WITHDRAWAL SYNDROME;

DIAGNOSIS, DIFFERENTIAL; HUMANS; OPIOID-RELATED DISORDERS; RISK FACTORS;

EID: 84867837044     PISSN: 00943509     EISSN: 15337294     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Centers for Disease Control and Prevention (CDC). Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010;59:705-709.
2. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315-1321.
3. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief. 2009;(22):1-8.4.
4. Substance Abuse and Mental Health Services Administration. Results From the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, Md: SAMHSA, Office of Applied Studies; 2010. NSDUH Series H-38A, HHS publication SMA 10-4856. Available at: http:// www.samhsa.gov/data/ NSDUH/2k9NSDUH/2k9Results.htm. Accessed August 22, 2012.
5. Hser YI, Huang D, Brecht ML, et al. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis. 2008;27:13-21.
6. Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2011;30:155-166.
7. George O, Koob GF. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2011;35:232-247.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev (DSM-IV-TR). Arlington, Va: American Psychiatric Association; 2000.
9. American Psychiatric Association. R 19 opioid use disorder. http://www.dsm5.org/ProposedRevisions/Pages/proposed revision.aspx?rid=460. Updated April 30, 2012. Accessed June 20, 2012.
10. Substance Abuse and Mental Health Services Administration. Results From the 2008 National Survey on Drug Use and Health: National Findings. Rockville, Md: SAMHSA, Office of Applied Studies; 2009. NSDUH Series H-36, HHS publication SMA 09-4434. Available at: http://www.samhsa.gov/data/ nsduh/2k8nsduh/ 2k8Results.htm. Accessed August 22, 2012.
11. Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94:135-140.
12. Skinner HA. The drug abuse screening test. Addict Behav. 1982;7:363-371. (Pubitemid 13162181)
13. US Preventive Services Task Force. Screening for Illicit Drug Use: U.S. Preventive Services Task Force Recommendation Statement. January 2008. Available at: http://www.uspreventive servicestaskforce.org/uspstf08/druguse/drugrs.htm. Accessed May 7, 2012.
14. Gourlay D, Caplan Y, Heit H. Urine Drug Testing in Clinical Practice: Dispelling the Myths and Designing Strategies. San Francisco, Calif: California Academy of Family Physicians; 2006.
15. Jackman R, Purvis J, Mallett B. Chronic nonmalignant pain in primary care. Am Fam Physician. 2008;78:1155-1162.
16. McBane S, Weigle N. Is it time to drug test your chronic pain patient? J Fam Pract. 2010;59:628-633.
17. Madras BK, Compton WM, Avula D, et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009;99:280-295.
18. The InSight Project Research Group. SBIRT outcomes in Houston: final report on InSight, a hospital district-based program for patients at risk for alcohol or drug use problems. Alcohol Clin Exp Res. 2009;33:1374-1381.
19. Borges G, Walters EE, Kessler RC. Associations of substance use, abuse, and dependence with subsequent suicidal behavior. Am J Epidemiol. 2000;151:781-789. (Pubitemid 30461142)
20. Prochaska JO, DiClemente CC. Stages and processes of selfchange of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51:390-395.
21. Smedslund G, Berg RC, Hammerstrom KT, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011;(5):CD008063.
22. Gryczynski J, Mitchell SG, Peterson TR, et al. The relationship between services delivered and substance use outcomes in New Mexico's Screening, Brief Intervention, Referral and Treatment (SBIRT) Initiative. Drug Alcohol Depend. 2011;118: 152-157.
23. Woody GE, Poole SA, Subramaniam G, et al. Extended vs shortterm buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300:2003-2011.
24. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68:1238-1246.
25. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101:491-503. (Pubitemid 43375613)
26. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:2613-2620.
27. Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69:215-232. (Pubitemid 36293934)
28. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. Res Publ Assoc Res Nerv Ment Dis. 1992;70:205-230.
29. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.
30. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19:4-16.
31. Office of National Drug Control Policy Reauthorization Act of 2006 (ONDCPRA), HR 6344, 109th Cong, 2nd Sess (2006).
32. Lewis JW, Walter D. Buprenorphine-background to its development as a treatment for opiate dependence. In: Blaine JD, ed. Buprenorphine: An Alternative Treatment for Opioid Dependence. Rockville, Md: National Institute on Drug Abuse; 1992:5-11. NIDA Research Monograph, No. 121. Available at: http://archives.drugabuse.gov/pdf/monographs/121.pdf. Accessed August 22, 2012.
33. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-580. (Pubitemid 24192243)
34. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenor-phine- naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75-78. (Pubitemid 46400304)
35. Hallinan R, Byrne A, Agho K, et al. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5:684-692. (Pubitemid 351337896)
36. Rapeli P, Fabritius C, Alho H, et al. Methadone vs. buprenorphine/ naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol. 2007;7:5.
37. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167:2469-2475. (Pubitemid 350254906)
38. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, Md: Substance Abuse and Mental Health Services Administration; 2004. Treatment Improvement Protocol (TIP) Series 40. DHHS publication SMA 04?3939.
39. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300:2303-2305.
40. Hulse GK, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66:1108-1115.
41. US Food and Drug Administration. FDA approves injectable drug to treat opioid-dependent patients. October 12, 2010. Available at: http://www.fda.gov/ NewsEvents/Newsroom/ PressAnnouncements/2010/ucm229109.htm. Accessed September 11, 2012.
42. Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther. 1972;13 (5 pt 1):633-637.
43. Stitzer M, Bigelow G, Lawrence C, et al. Medication takehome as a reinforcer in a methadone maintenance program. Addict Behav. 1977;2:9-14. (Pubitemid 8172123)
44. Code of Federal Regulations. Title 42.8.12. Federal Opioid Treatment Standards. October 2010.
45. Johnson RE. Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290-1297.
46. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387-395.
47. Ball JC, Lange WR, Myers CP, et al. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29:214-226.
48. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365-374. (Pubitemid 44127539)
49. Defulio A, Everly JJ, Leoutsakos JM, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend. 2012;120:48-54.
50. Savage SR. Management of opioid medications in patients with chronic pain and risk of substance misuse. Curr Psychiatry Rep. 2009;11:377-384.